Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients

Table 1 Demographics, therapy and prognosis of esophageal cancer patients

	Total		ESCC		EAC
	n	5Y-SR (%)	n	5Y-SR (%)	n	5Y-SR (%)
Total study cohort	195	27	90	27	105	26
Median age (yr)	60.4	-	60	-	62	-
Gender
Male	155	28	61	25	94	31
Female	40	26	29	32	11	12
Therapy
Surgery only	89	29	32	27	57	31
RTx/CTx + surgery	106	27	58	27	48	28
T-category
pT2	30	46	6	62	24	43
cT/pT3	165	25	84	24	81	26
Endoscopic biopsy	104	25	58	22	46	29

5Y-SR: 5-year survival rate; EAC: Adenocarcinoma of the esophagus; ESCC: Squamous cell carcinoma of the esophagus; pT: Pathologic tumor; cT: Clinical tumor category; RTx/CTx: Neoadjuvant radio-/chemotherapy.

Table 2 Podoplanin expression in esophageal cancer squamous cell carcinoma of the esophagus vs adenocarcinoma of the esophagus

	Total		ESCC		EAC
	n	Podoplanin > 5% (HPE, %)	n	Podoplanin > 5% (HPE, %)	n	Podoplanin > 5% (HPE, %)
Total study cohort	195	13	90	26	105	2
Gender
Male	155	10	61	23	94	1
Female	40	25	29	32	11	9
Therapy
Surgery only	89	19	32	50	57	2
RTx/CTx + surgery	106	7	58	11	48	2
T-category
pT2	30	3	6	17	24	0
cT/pT3	165	14	84	27	81	3
Endoscopic biopsy	104	7	58	38	46	2

Biopsies and resected specimen of patients with adeno- and squamous cell carcinoma, scoring by immunohistochemically stained D2-40. HPE: High podoplanin expression; EAC: Adenocarcinoma of the esophagus; ESCC: Squamous cell carcinoma of the esophagus; pT: Pathologic tumor; cT: Clinical tumor category; RTx/CTx: Neoadjuvant radio-/chemotherapy.

Table 3 Podoplanin expression and tumor progression

Resected tissue	Score	Podoplanin, %	Patients, n	Patients, %
pT2, n = 6	1	0-5	5	83
	2	6-35	1	17
	3	36-65	0	0
pT3/4, n = 26	1	0-5	11	43
	2	6-35	10	38
	3	36-65	5	19
pN0, n = 11	1	0-5	7	64
	2	6-35	2	18
	3	36-65	2	18
pN+, n = 21	1	0-5	9	43
	2	6-35	9	43
	3	36-65	3	14

Resected tumor specimen of non-pretreated primary surgery squamous cell carcinoma of the esophagus patients, n = 32; pT: Pathologic tumor category; pN0: No lymph node metastases; pN+: Lymph nodes involved, scoring by immunohistochemical staining of D2-40.

Table 4 Expression of podoplanin protein differs between tissues resected from neoadjuvantly treated and non-pretreated direct surgery squamous cell carcinoma of the esophagus patients

Resected tissue	Podoplanin		Patients
	Score	%	n	%
RTx/CTx + surgery	1	0-5	51	89
	2	6-35	5	9
	3	36-65	2	2
Primary surgery non-pretreated	1	0-5	16	50
	2	6-35	11	34
	3	36-65	5	16

Resected tissue specimen: neoadjuvant chemoradiation squamous cell carcinoma of the esophagus (ESCC) patients, n = 58 and non-pretreated direct surgery ESCC patients, n = 32, scoring by immunohistochemically stained D2-40, P < 0.001. RTx/CTx: Neoadjuvant radio-/chemotherapy.

Table 5 Podoplanin expression pre- and post-neoadjuvant chemoradiaton

Endoscopic biopsies pre RTx/CTx		Post RTx/CTx resected tissue
Podoplanin expression	Patients, n	0-5%	6%-35%	36%-65%	> 65%
0-5%	35	34	1	0	0
6%-35%	14	10	3	1	0
36%-65%	3	3	0	0	0
> 65%	4	3	1	0	0

Comparison of matched biopsies and resected specimen of 56 patients, scoring by immunohistochemically stained D2-40, P < 0.001. RTx/CTx: Neoadjuvant radio-chemotherapy.